118 related articles for article (PubMed ID: 31949399)
1. Economic evaluation of cervical cancer screening strategies in urban China.
Ma L; Wang Y; Gao X; Dai Y; Zhang Y; Wang Z; Wang X; Wang L; Jiang J; Jing X; Yang C; Zhao F; Lang J; Qiao Y
Chin J Cancer Res; 2019 Dec; 31(6):974-983. PubMed ID: 31949399
[TBL] [Abstract][Full Text] [Related]
2. [Cost-effectiveness analysis of cervical cancer screening strategies in urban China].
Peng JR; Tao SY; Wen Y; Yang X; Ma JQ; Zhao F; Chen ZY; Zhang GT; Qiao YL; Zhao FH; Yang CX
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):154-160. PubMed ID: 30862148
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of artificial intelligence-assisted liquid-based cytology testing for cervical cancer screening in China.
Shen M; Zou Z; Bao H; Fairley CK; Canfell K; Ong JJ; Hocking J; Chow EPF; Zhuang G; Wang L; Zhang L
Lancet Reg Health West Pac; 2023 May; 34():100726. PubMed ID: 37283979
[TBL] [Abstract][Full Text] [Related]
4. The impact of alternate HPV vaccination and cervical screening strategies in Japan: a cost-effectiveness analysis.
Palmer MR; Saito E; Katanoda K; Sakamoto H; Hocking JS; Brotherton JML; Ong JJ
Lancet Reg Health West Pac; 2024 Mar; 44():101018. PubMed ID: 38404421
[TBL] [Abstract][Full Text] [Related]
5. Decision-analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
GMS Health Technol Assess; 2010 Apr; 6():Doc05. PubMed ID: 21289878
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness analysis on the once-in-a-lifetime cervical cancer screening program for women living in rural and urban areas of China].
Xu H; Zhao FH; Gao XH; Hu SY; Chen JF; Liu ZH; Xu XL; Gao LM; Liu QG; Ma L; Liu YJ; Qiao YL
Zhonghua Liu Xing Bing Xue Za Zhi; 2013 Apr; 34(4):399-403. PubMed ID: 23937850
[TBL] [Abstract][Full Text] [Related]
7. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening.
Kitchener HC; Almonte M; Gilham C; Dowie R; Stoykova B; Sargent A; Roberts C; Desai M; Peto J;
Health Technol Assess; 2009 Nov; 13(51):1-150, iii-iv. PubMed ID: 19891902
[TBL] [Abstract][Full Text] [Related]
8. Epidemiologic and Health Economic Evaluation of Cervical Cancer Screening in Rural China.
Zhao F; Wen Y; Li Y; Tao S; Ma L; Zhao Y; Dang L; Wang Y; Zhao F; Lang J; Qiao Y; Yang CX
Asian Pac J Cancer Prev; 2020 May; 21(5):1317-1325. PubMed ID: 32458639
[TBL] [Abstract][Full Text] [Related]
9. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
Wong G; Howard K; Webster A; Chapman JR; Craig JC
Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
[TBL] [Abstract][Full Text] [Related]
10. [Economic evaluation of fifteen cervical cancer screening strategies in rural China].
Wang YY; Wang ZJ; Zhang Y; Gao XH; Yang CX; Zhao FH; Qiao YL; Ma L; Lang JH
Zhonghua Fu Chan Ke Za Zhi; 2019 Dec; 54(12):840-847. PubMed ID: 31874474
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system.
Chow IH; Tang CH; You SL; Liao CH; Chu TY; Chen CJ; Chen CA; Pwu RF
Br J Cancer; 2010 Dec; 103(12):1773-82. PubMed ID: 21102588
[TBL] [Abstract][Full Text] [Related]
12. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis.
Zou Z; Fairley CK; Ong JJ; Hocking J; Canfell K; Ma X; Chow EPF; Xu X; Zhang L; Zhuang G
Lancet Glob Health; 2020 Oct; 8(10):e1335-e1344. PubMed ID: 32971056
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
Goldhaber-Fiebert JD; Stout NK; Salomon JA; Kuntz KM; Goldie SJ
J Natl Cancer Inst; 2008 Mar; 100(5):308-20. PubMed ID: 18314477
[TBL] [Abstract][Full Text] [Related]
14. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
15. VIA/VILI is more suitable for cervical cancer prevention in Chinese poverty-stricken region: a health economic evaluation.
Xie Y; Tan X; Shao H; Liu Q; Tou J; Zhang Y; Luo Q; Xiang Q
BMC Public Health; 2017 Jan; 17(1):118. PubMed ID: 28122530
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Different Cervical Screening Strategies in Islamic Republic of Iran: A Middle-Income Country with a Low Incidence Rate of Cervical Cancer.
Nahvijou A; Daroudi R; Tahmasebi M; Amouzegar Hashemi F; Rezaei Hemami M; Akbari Sari A; Barati Marenani A; Zendehdel K
PLoS One; 2016; 11(6):e0156705. PubMed ID: 27276093
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of an HPV self-collection campaign in Uganda: comparing models for delivery of cervical cancer screening in a low-income setting.
Campos NG; Tsu V; Jeronimo J; Njama-Meya D; Mvundura M; Kim JJ
Health Policy Plan; 2017 Sep; 32(7):956-968. PubMed ID: 28369405
[TBL] [Abstract][Full Text] [Related]
18. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.
Karnon J; Peters J; Platt J; Chilcott J; McGoogan E; Brewer N
Health Technol Assess; 2004 May; 8(20):iii, 1-78. PubMed ID: 15147611
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
